DrugRepV Browse Page

DrugRepV browse page allows user to take a glance of the particular antiviral agent.Fields in the webpage is hylerlinked ot various external repositories like DrugBank, PubChem, Clinicaltrials.gov,and PubMed.User can explore the biological, Clinical, Chemical, and Structural details of every repurposed drug candidate.By clicking on the table header arrows, user can sort entries in ascending or descending order.


Total number of Records for RLuc expression are 6

DrugRepV_ID	Antiviral Name	Drug type	Primary Indication	Secondary Indication	Strain	Pathways	Assay	Activity	Clinical Status	References
DrugRepV_5217	Ammonium Chloride	Blood and Blood Forming Organs; Genito Urinary System and Sex Hormones	NA	Rift Valley fever virus	RVF-VLPs	NA	RLuc expression	Decrease (90.3 %)	Approved	21994655
DrugRepV_5218	Guanidine	Musculo-Skeletal System	Muscle weakness | Myasthenic syndrome of Eaton-Lambert	Rift Valley fever virus	RVF-VLPs	NA	RLuc expression	No significant effect (54.2 %)	Approved	21994655
DrugRepV_5219	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Rift Valley fever virus	RVF-VLPs	NA	RLuc expression	Decrease (87.2 %)	Approved	21994655
DrugRepV_5220	Actinomycin D	Antineoplastic and Immunomodulating Agents	Cancer	Rift Valley fever virus	RVF-VLPs	NA	RLuc expression	Decrease (86.8 %)	Approved	21994655
DrugRepV_5221	Monensin	Antibiotics	Bacterial infections	Rift Valley fever virus	RVF-VLPs	NA	RLuc expression	Decrease (97.9 %)	Experimental, Vet approved	21994655
DrugRepV_5222	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Rift Valley fever virus	RVF-VLPs	NA	RLuc expression	Decrease (91.1 %)	Approved	21994655